21 – 30 of 59
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
High-Dose Radioimmunotherapy Combined With Extracorporeal Depletion in a Syngeneic Rat Tumor Model
(
- Contribution to journal › Article
-
Mark
Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
(
- Contribution to journal › Article
-
Mark
Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
(
- Contribution to journal › Article
-
Mark
Toxicity-Reducing Potential of Extracorporeal Affinity Adsorption Treatment in Combination With the Auristatin-Conjugated Monoclonal Antibody BR96 in a Syngeneic Rat Tumor Model
(
- Contribution to journal › Article
- 2009
-
Mark
Risk of Dying From Prostate Cancer in Men Randomized to Screening Differences Between Attendees and Nonattendees
(
- Contribution to journal › Article
- 2008
-
Mark
Liposarcoma : outcome based on the Scandinavian Sarcoma Group register
(
- Contribution to journal › Article
-
Mark
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma - Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
(
- Contribution to journal › Article
-
Mark
The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate.
(
- Contribution to journal › Article
- 2007
-
Mark
Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group
(
- Contribution to journal › Article
-
Mark
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
(
- Contribution to journal › Article